Tags

Type your tag names separated by a space and hit enter

Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus.
Br J Pharmacol. 2008 Mar; 153(5):886-93.BJ

Abstract

BACKGROUND AND PURPOSE

Diabetes-associated vascular dysfunction contributes to increased cardiovascular risk. We investigated whether the phosphodiesterase-5 inhibitor sildenafil would improve vascular function in diabetic rats.

EXPERIMENTAL APPROACH

Male Wistar rats were injected with streptozotocin (50 mg kg(-1), i.v.) to induce insulin-deficient diabetes. Direct effects of sildenafil as well as modification of endothelium-dependent and -independent vasorelaxation were investigated in vitro. The effects of acute and chronic (2 week) treatment in vivo of sildenafil on vascular function were also characterized in isolated aortic segments in organ bath chambers 4 weeks after diabetes induction.

KEY RESULTS

Sildenafil induced a concentration-dependent vasorelaxation, which was attenuated by the nitric oxide (NO) synthase inhibitor, N(G)-nitro-L-arginine. Acetylcholine-induced endothelium-dependent as well as endothelium-independent relaxation induced by the NO donor, DEA-NONOate, was significantly reduced in aortae from diabetic rats. Incubation with sildenafil in vitro normalized both endothelium-dependent and -independent relaxation in aortae from diabetic rats. Acute as well as chronic in vivo treatment with sildenafil resulted in enhanced endothelium-dependent and -independent vasorelaxation. Superoxide formation was increased in diabetes, associated with enhanced membrane expression of the NAD(P)H oxidase subunit gp91(phox) and Rac, which were both reduced by chronic treatment with sildenafil.

CONCLUSIONS AND IMPLICATIONS

We demonstrate that sildenafil treatment rapidly and chronically improves vascular relaxation in diabetic rats. Treatment with sildenafil might provide a similarly beneficial effect in diabetic patients.

Authors+Show Affiliations

Medizinische Klinik und Poliklinik I, Universitätsklinikum Würzburg, Julius-Maximilians-Universität Würzburg, Würzburg, Bavaria, Germany. a.schaefer@medizin.uni-wuerzburg.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17891166

Citation

Schäfer, A, et al. "Improvement of Vascular Function By Acute and Chronic Treatment With the PDE-5 Inhibitor Sildenafil in Experimental Diabetes Mellitus." British Journal of Pharmacology, vol. 153, no. 5, 2008, pp. 886-93.
Schäfer A, Fraccarollo D, Pförtsch S, et al. Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus. Br J Pharmacol. 2008;153(5):886-93.
Schäfer, A., Fraccarollo, D., Pförtsch, S., Flierl, U., Vogt, C., Pfrang, J., Kobsar, A., Renné, T., Eigenthaler, M., Ertl, G., & Bauersachs, J. (2008). Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus. British Journal of Pharmacology, 153(5), 886-93.
Schäfer A, et al. Improvement of Vascular Function By Acute and Chronic Treatment With the PDE-5 Inhibitor Sildenafil in Experimental Diabetes Mellitus. Br J Pharmacol. 2008;153(5):886-93. PubMed PMID: 17891166.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus. AU - Schäfer,A, AU - Fraccarollo,D, AU - Pförtsch,S, AU - Flierl,U, AU - Vogt,C, AU - Pfrang,J, AU - Kobsar,A, AU - Renné,T, AU - Eigenthaler,M, AU - Ertl,G, AU - Bauersachs,J, Y1 - 2007/09/24/ PY - 2007/9/25/pubmed PY - 2008/5/16/medline PY - 2007/9/25/entrez SP - 886 EP - 93 JF - British journal of pharmacology JO - Br J Pharmacol VL - 153 IS - 5 N2 - BACKGROUND AND PURPOSE: Diabetes-associated vascular dysfunction contributes to increased cardiovascular risk. We investigated whether the phosphodiesterase-5 inhibitor sildenafil would improve vascular function in diabetic rats. EXPERIMENTAL APPROACH: Male Wistar rats were injected with streptozotocin (50 mg kg(-1), i.v.) to induce insulin-deficient diabetes. Direct effects of sildenafil as well as modification of endothelium-dependent and -independent vasorelaxation were investigated in vitro. The effects of acute and chronic (2 week) treatment in vivo of sildenafil on vascular function were also characterized in isolated aortic segments in organ bath chambers 4 weeks after diabetes induction. KEY RESULTS: Sildenafil induced a concentration-dependent vasorelaxation, which was attenuated by the nitric oxide (NO) synthase inhibitor, N(G)-nitro-L-arginine. Acetylcholine-induced endothelium-dependent as well as endothelium-independent relaxation induced by the NO donor, DEA-NONOate, was significantly reduced in aortae from diabetic rats. Incubation with sildenafil in vitro normalized both endothelium-dependent and -independent relaxation in aortae from diabetic rats. Acute as well as chronic in vivo treatment with sildenafil resulted in enhanced endothelium-dependent and -independent vasorelaxation. Superoxide formation was increased in diabetes, associated with enhanced membrane expression of the NAD(P)H oxidase subunit gp91(phox) and Rac, which were both reduced by chronic treatment with sildenafil. CONCLUSIONS AND IMPLICATIONS: We demonstrate that sildenafil treatment rapidly and chronically improves vascular relaxation in diabetic rats. Treatment with sildenafil might provide a similarly beneficial effect in diabetic patients. SN - 0007-1188 UR - https://www.unboundmedicine.com/medline/citation/17891166/Improvement_of_vascular_function_by_acute_and_chronic_treatment_with_the_PDE_5_inhibitor_sildenafil_in_experimental_diabetes_mellitus_ L2 - https://doi.org/10.1038/sj.bjp.0707459 DB - PRIME DP - Unbound Medicine ER -